FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
|Articles|August 17, 2006
IAC: The HIV Clinical ExperienceA MULTIMEDIA REPORT - Day 4
Author(s)Zach Wise
TORONTO -- This Special Report from Zach Wise, a contributing photographer for MedPage Today, provides a multimedia portrayal of the activities at the 16th Annual International AIDS Conference here.
Advertisement
Advertisement
Related to this article
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
3
FAQ: What the Endocrine Society’s New Scientific Statement Means for Obesity Treatment
4
FDA Approves Finerenone for CKD Associated With Type 1 Diabetes
5